Rivaroxaban in Patients with ACS: Do the Data Provide Support? - C. Michael Gibson, MD

↳ This is a section part of Moment: CRT 2016 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.

add to passport

$12.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Rivaroxaban in Patients with ACS: Do the Data Provide Support? presented by C. Michael Gibson, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

add to passport

$12.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

Update in advances in ACS & AMI Management

Other Components in this Moment

Oral Anticoagulants for Atrial Fibrillation: Is There a Winner? - C. Michael Gibson, MD

Dabigatran: Are There Any Concerns? - Neal Kleiman, MD, FSCAI

Should We Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? - Dominick Angiolillo, MD, PhD, FSCAI

Rivaroxaban in Patients with ACS: Do the Data Provide Support? - C. Michael Gibson, MD

What Did We Learn from the WOEST Studies and Protocols? Are We Ready to Drop Aspirin From Triple Therapy? - Sunil Rao, MD, FSCAI

Is RNA Aptamer Technology Dead? - A. Michael Lincoff, MD

Loading Simple Education